Mary Gonzales, APRN
Family · Wichita, KSNPI 1659687580
Payments from drug & device makers
Across 664 payments — averaging $131.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$76K
- Viiv Healthcare Company$6K
- AbbVie$1K
- Johnson & Johnson$396
- Merck$395
- Janssen Scientific Affairs, LLC$364
- plus $3K from 31 others
What the payments were for
- Consulting fees$1,8002%
- Speaking & faculty fees$52,29460%
- Travel & lodging$19,30422%
- Food & beverage$13,64716%
- Education$3070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 301 | $76,102 |
| Viiv Healthcare Company | 104 | $6,383 |
| AbbVie | 76 | $1,060 |
| Johnson & Johnson(2 entities) | 30 | $396 |
| Merck | 25 | $395 |
| Janssen Scientific Affairs, LLC | 5 | $364 |
| Janssen Products, LP | 4 | $341 |
| AstraZeneca | 17 | $293 |
| Napo Pharmaceuticals Inc | 11 | $244 |
| Exact Sciences | 11 | $207 |
| Otsuka America Pharmaceutical, Inc. | 9 | $195 |
| Eisai Inc. | 6 | $145 |
| Pfizer | 8 | $134 |
| Lilly USA, LLC | 8 | $122 |
| Madrigal Pharmaceuticals | 1 | $114 |
| Novo Nordisk | 6 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $79 |
| Abbott | 3 | $71 |
| GSK | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Ardelyx, Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 4 | $51 |
| EMD Serono, Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| Halozyme Inc | 2 | $33 |
| Dexcom, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Vertex | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Globus Medical | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Biogen | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,352 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 495 | $2,007,657 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 69 | $323,326 |
| DovatoDolutegravir Sodium/Lamivudine | 82 | $236,213 |
| DescovyEmtricitabine/Tenofov Alafenam | 91 | $206,580 |
| Egrifta SvTesamorelin Acetate | 23 | $168,546 |
| OxycontinOxycodone Hcl | 90 | $142,653 |
| CabenuvaCabotegravir/Rilpivirine | 21 | $139,035 |
| OzempicSemaglutide | 126 | $135,237 |
| RukobiaFostemsavir Tromethamine | 13 | $115,253 |
| TivicayDolutegravir Sodium | 44 | $103,659 |
| VraylarCariprazine Hcl | 69 | $101,817 |
| PrezcobixDarunavir/Cobicistat | 38 | $99,956 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $97,660 |
| MounjaroTirzepatide | 83 | $90,686 |
| XifaxanRifaximin | 24 | $73,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $76,102 | $2,281,624603 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Rukobia, Tivicay | $6,383 | $594,159160 claims |
| Janssen Products, LPSymtuza | $341 | $323,32669 claims |
| AbbVieVraylar, Ubrelvy, Linzess | $1,060 | $149,068129 claims |
| Novo NordiskOzempic | $91 | $135,237126 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $396 | $124,50168 claims |
| Lilly USA, LLCMounjaro | $122 | $90,68683 claims |
| MerckJanuvia, Isentress, Janumet | $395 | $78,36887 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $70 | $76,581126 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $55 | $73,34824 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $293 | $63,430138 claims |
| PfizerEliquis | $134 | $59,19775 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
- Zohra HussainiKansas City$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.